4-(Aminomethyl)-2-methylbenzamide | 164648-64-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(Aminomethyl)-2-methylbenzamide
• CAS: 164648-64-0
• 化学式: C₉H₁₂N₂O
• 分子量: 164.2
• InChiKey: LDNPAWDDWCILGA-UHFFFAOYSA-N

物化性质

• 沸点：
  351.5±25.0 °C(Predicted)
• 密度：
  1.096±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  69.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2924299090
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340+P312,P305+P351+P338,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335

文献信息

• [EN] BENZYLAMINE DERIVATIVES<br/>[FR] DÉRIVÉS DE BENZYLAMINE
  申请人：KALVISTA PHARMACEUTICALS LTD

  公开号：WO2014108679A1

  公开（公告）日：2014-07-17

  The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R3, R5 to R9, A, P, V, W, X, Y and Z are as defined herein.

  本发明提供了化合物的公式(I)：包含这种化合物的组合物；在治疗中使用这种化合物（例如在涉及血浆激肽酶活性的疾病或病况的治疗或预防中）；以及使用这种化合物治疗患者的方法；其中R1至R3，R5至R9，A，P，V，W，X，Y和Z如本文所定义。
• Microsomal Triglyceride transfer protein inhibitor
  申请人：Pfizer Inc

  公开号：US20040132779A1

  公开（公告）日：2004-07-08

  The present invention provides inhibitors of microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (Apo B) secretion having Formula (I) which are useful for the treatment of obesity and related diseases, as well as prevention and treatment of atherosclerosis and its clinical sequelae, for lowering serum lipids, and in the prevention and treatment of related diseases. The invention further relates to pharmaceutical compositions comprising the compounds of the present invention and to methods of treating obesity, atherosclerosis, and related diseases and/or conditions with the compounds of the present invention, either alone or in combination with other pharmaceutical agents, including lipid-lowering agents. 1

  本发明提供了具有式（I）的微粒体三酰甘油转移蛋白（MTP）和/或载脂蛋白B（Apo B）分泌抑制剂，用于治疗肥胖和相关疾病，以及预防和治疗动脉粥样硬化及其临床后遗症，降低血清脂质，以及预防和治疗相关疾病。该发明还涉及包含本发明化合物的药物组合物，以及使用本发明化合物单独或与其他药物剂（包括降脂药物）联合治疗肥胖、动脉粥样硬化和相关疾病和/或症状的方法。
• Inhibitors of factor Xa
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20040116399A1

  公开（公告）日：2004-06-17

  Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.

  本发明揭示了一种具有对哺乳动物因子Xa活性的新化合物、其盐和相关组合物。这些化合物在体外或体内用于预防或治疗凝血障碍。
• BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA
  申请人：Zhu Bing-Yan

  公开号：US20090131411A1

  公开（公告）日：2009-05-21

  Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.

  本发明涉及一种新型苯甲酰胺类化合物，包括其药学上可接受的异构体，盐，水合物，溶剂合物和前药衍生物，具有对哺乳动物因子Xa的活性。本发明还涉及含有这种化合物的组合物。这些化合物和组合物在体内或体外用于预防或治疗凝血障碍。
• Benzamides and related inhibitors of factor Xa
  申请人：Zhu Bing-Yan

  公开号：US20070021472A1

  公开（公告）日：2007-01-25

  Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.

  本发明涉及一种新型苯甲酰胺类化合物，包括其药学上可接受的异构体、盐、水合物、溶剂合物和前药衍生物，其对哺乳动物因子Xa具有活性。本发明还描述了含有这种化合物的组合物。这些化合物和组合物在体外或体内用于预防或治疗凝血障碍。